"I think that's one of the biggest concerns from the FDA side," LaValle, who chairs the International Peptide Society, said
[DOI] [PubMed] [Google Scholar] [55].Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, et al
In a review of 22 studies on supplemental or prescription fish oil preparations that evaluated the effects of EPA and DHA on blood lipids, DHA was found to decrease triglyceride levels by 6.8% and increase HDL levels by 5.9%
What this means in practice: Compounding pharmacies that halted GHK-Cu production in 2023 can begin preparing to restock (once July guidance is finalized) Clinicians prescribing peptide protocols will have legitimate, pharmaceutical-grade sourcing options again Patients who've been sourcing from unregulated channels will have access to properly tested product Quality and safety will improve compounded products from licensed facilities must meet USP standards for purity and sterility What This Doesn't Mean This is not FDA approval
What can I expect from treatment
doi:10.5534/wjmh.200130